Reduction in Symptoms After Laser Therapy With Acorn aHFS

NCT06336135 | Completed

• 1 other identifier: 23-001
• Study Type: observational
• Target: 11
• Locations: 1 country
• Sites: 1

Brief Summary

This study evaluates the severity and duration of symptoms experienced after laser therapy comparing four post-procedure topical products. Each product is applied to an individual region of interest (5 cm diameter) on the back or décolleté according to randomization code after laser therapy. The subject, blind to the product applied to each of 4 regions of interest, assesses eight symptoms daily for 14 days. Photography is performed daily.

Conditions

Skin Aging

Keywords

skin, aging, rejuvenation, laser resurfacing, autologous secretome

Outcome Measures

Primary Outcomes (1)

• Reduction in severity and duration of symptoms

  Each region of interest will be evaluated daily for the severity and duration of eight symptoms

  2 weeks

Interventions

autologous hair follicle derived secretome OTHER

aHFS is a cosmetic topical intended to be applied to the human body after skin resurfacing cosmetic procedures. aHFS is produced from the plucked hair follicles of each individual, making it autologous.

Also known as: Acorn autologous hair follicle secretome, aHFS

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Subjects are healthy adults receiving laser skin rejuvenation therapy.

You may qualify if:

• Male or Female
• Age: ≥18 and ≤60 years
• Any skin tone Fitzpatrick score 1-2 (light), 3-4 (medium), 5-6 (dark)
• Competent and willing to provide written, informed consent to participate in all study activities

You may not qualify if:

• Pregnant women
• Are participating/have participated in another interventional clinical trial in the last 30 days which may confound the results of this study, unless approved by Sponsor
• Use of retinoids 7 days prior to the procedure
• Active cutaneous infections in the treatment area
• Diseases that could inhibit healing, such as scleroderma, or other cutaneous conditions that could confound study results
• Subjects unable to communicate with the investigator and staff
• Any health condition that in the investigator's opinion should preclude participation in this study

Sponsors & Collaborators

• Acorn Biolabs Inc.: lead

Study Sites (1)

Rejuuv Medi Spa

Markham, Ontario, L3R0M3, Canada

Location

Study Officials

• Lisa Campbell, PhD

  Acorn Biolabs Inc.

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 22, 2024
• First Posted: March 28, 2024
• Study Start: March 25, 2024
• Primary Completion: December 2, 2025
• Study Completion: December 2, 2025
• Last Updated: December 12, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)